<figure><img src="image_1.png" /></figure>

# Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

Correction to: *Nature Medicine* https://doi.org/10.1038/s41591-023-02572-5, published online 14 September 2023.

https://doi.org/10.1038/s41591-023-02624-w

Published online: 9 October 2023

<figure><img src="image_2.png" /></figure>

Check for updates

Roch Houot®, Emmanuel Bachy®, Guillaume Cartron, François-Xavier Gros®, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Rémy Duléry, Catherine Thieblemont®, Magalie Joris, Fabrice Jardin®, Sylvain Choquet®, Olivier Casasnovas, Gabriel Brisou, Morgane Cheminant, Jacques-Olivier Bay, Francisco Llamas Gutierrez, Cédric Menard, Karin Tarte®, Marie-Hélène Delfau, Cédric Portugues, Emmanuel Itti, Xavier Palard-Novello, Paul Blanc-Durand, Yassine Al Tabaa, Clément Bailly, Camille Laurent® & François Lemonnier

In the version of this article initially published, the title of the paper, now reading "Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial," appeared incorrectly as "Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial." The title has been updated in the HTML and PDF versions of the article.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023